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and risk group. The time horizon was one year, without dis-
counting. Sensitivity analysis was performed to account for
uncertainty. RESULTS: Vytorin was found to be most effective
with 90% of patients successfully treated to goal compared to
78.2%, 82.1%, and 82.2% for simvastatin, atorvastatin, and
rosuvastatin, respectively. Vytorin was the preferred strategy,
dominating other treatments at a cost of $431 annually per
patient successfully treated to goal. CONCLUSION: Using lit-
erature-derived estimates for % LDL lowering efﬁcacy, we com-
pared high-potency antilipidemics based on the percentage of
patients successfully treated to goal. Estimates were similar to
outcomes reported in clinical trials. At DoD drug acquisition
costs, Vytorin appeared to be the most cost effective.
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OBJECTIVES: In Mexico, hypertension and hypercholes-
terolemia are the main causes of cardiovascular risk and death
in adult population. Prevalence of hypertension and hypercho-
lesterolemia are estimated in 30% and 43%, respectively. The
purpose of this study was to evaluate the cost—effectiveness of
amlodipine/atorvastatin in a single pill therapy compared to
other local therapies for patients with both diseases from the
Mexican health care payer’s perspective. METHODS: We used
a ﬁve-year Markov analysis model to estimate costs and effec-
tiveness. Effectiveness measures were the % of patients with full
compliance and % of patients with fatal or non-fatal cardiovas-
cular events. Transition probabilities were obtained from inter-
national published literature. Comparators used in the model
were: amlodipine 5 mg, felodipine 5 mg, nifedipine 30 mg, cap-
topril 75 mg, enalapril 20 mg, losartan 50 mg all in combination
with pravastatin 10 mg (separate pills) vs. the comparator
amlodipine 5 mg + atorvastatin 10 mg (single-pill therapy). Esti-
mation of resource use was performed employing hospital
records from ﬁve hospitals of the Social Security Mexican Insti-
tute-IMSS in Mexico City (n = 75). They included hospitaliza-
tion, ICU, emergency, outpatient services and drugs. Costs and
effectiveness measures were discounted 3% annually. One-way
and probabilistic sensitivity analyses were performed and accept-
ability curves were constructed. RESULTS: The single-pill
therapy showed better compliance with 12.5% vs. 9.6% shown
in average by the other combinations considered (p < 0.01). This
higher compliance of the single-pill therapy yielded a signiﬁcant
reduction in the number of cardiovascular events, deaths and
expected costs (cost saving strategy). Alongside the time horizon
used, the model estimated that the single-pill therapy could save
US$2.8 per patient with both diseases. Sensitivity analyses
showed the same results. CONCLUSION: In Mexico, amlodip-
ine/atorvastatin within a single-pill showed better clinical and
economic outcomes in comparison to other combinations of
antihypertensive and statins inside an institutional setting. These
results should be considered by Mexican decision-makers in
future cost-containment policies.
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OBJECTIVES: To compare cost-effectiveness (CE) of rosuvas-
tatin (RSV) and ezetimibe/simvastatin (E/S) in patients with
treated dyslipidemia to assess achievement of treatment goals
established by Adult Treatment Panel III (ATPIII). METHODS:
Clinical data was obtained from the ﬁles of dyslipidemic patients
that attended from January 2004 to December 2005 to a Car-
diology Hospital in Mexico City. Patients treated with either
RSV 10 mg/day or E/S 10/20 mg/day and with lipid determina-
tions before (basal) and after 8 weeks of treatment were
included. The perspective of the analysis was from the point of
view of the provider, and the cost of the drugs that was obtained
by a local wholesaler (NADRO, Oct 2006). Effectiveness was
measured with subrogates end points, achieving ATPIII lipid
goals and lowering LDL-C levels. The precision of the CE esti-
mate was assessed by the bootstrap method, using 1000 re-sam-
plings and by net monetary beneﬁt approach. Horizon time was
8 weeks. Acceptability curves were built to assess uncertainty.
Sensitivity analysis included threshold, one-way and scenario
assessment. RESULTS: Ninety-eight patients received RSV (age
63.1 ± 12.4 years) and 89 patients received E/S (age 65.8 ± 12.8
years). In the RSV group 81.4% and 46.4% patients achieved
2001 and 2004 lipid goals respectively, versus 58.4% and 31.5%
E/S patients (p < 0.01). LDL-C mean percentage reduction was:
RSV −46.7 ± 13.6 versus E/S −35 ± 21.3 (p < 0.001). Average
per patient costs in USD was 94.35 for RSV (85.4–109.8) and
143.01 for E/S (127.42–161.64). RSV showed to be less costly
and more effective than E/S for achieving ATPIII goals and reduc-
ing LDL-C levels. Acceptability showed that independently of
willingness to pay, RSV is CE in 97% of scenarios compared to
E/S. Sensitivity analysis showed the robustness of results. CON-
CLUSION: On clinical practice RSV is more CE in attainment
of ATPIII goals and lowering LDL-C levels in Mexican patients.
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OBJECTIVES: To determine the lifetime costs and morbidity
associated with nonadherence to lipid-lowering and antihyper-
tensive therapy in a population of hypertensive patients with
additional cardiovascular risk factors. METHODS: A Markov
model was constructed to assess the lifetime costs and outcomes
associated with different levels of adherence to lipid-lowering
and antihypertensive therapy in a cohort of patients aged 40 to
79 years. Three adherence scenarios were considered: no treat-
ment, typical adherence, and ideal adherence. Patient charac-
teristics were modeled on those of participants in the 
Anglo-Scandinavian Cardiac Outcomes Trial—Lipid-Lowering
Arm (ASCOT-LLA); event probabilities for coronary heart
disease and stroke were estimated using risk prediction algo-
rithms from the Framingham Heart Study. The ideal adherence
scenario modeled the experience of ASCOT-LLA patients, with
adherence levels based on those observed in the trial. The typical
adherence scenario employed real-world adherence rates and
annual transitions based on prescription records from the Cali-
fornia Medicaid system. Risk reductions for the various adher-
ence states in this scenario were drawn from clinical trials. Model
outputs included frequencies of primary and secondary heart
disease and stroke, life expectancy, and pharmacy-related and
event-speciﬁc costs in 2006 USD. RESULTS: The mean number
of events per patient was 0.738 in the no treatment scenario,
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0.610 for typical adherence, and 0.441 for ideal adherence.
Mean life expectancy was 14.73 years for no treatment, 15.07
years for typical adherence, and 15.49 for ideal adherence. The
incremental cost effectiveness ratio per life-year gained was
$30,585 between typical adherence and no treatment, and
$22,121 between ideal adherence and typical adherence. CON-
CLUSION: Nonadherence to lipid-lowering and antihyperten-
sive therapy contributes signiﬁcantly to the clinical and economic
burden of heart disease and stroke in the population considered.
Patients with typical adherence levels receive approximately
50% of the risk reduction seen in clinical trials with controlled
levels of ideal adherence.
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OBJECTIVES: To determine the cost-effectiveness of providing
aspirin, low molecular weight heparin (LMWH), or compression
stockings to air travelers for the prevention of air traveler throm-
bosis (ATT). METHODS: A pharmacoeconomic model was con-
structed from the perspective of a 1.5 million member US
managed care organization (MCO). The model had a one-year
time horizon to coincide with typical budgetary cycles. Air travel
estimates were calculated using 2005 Federal Aviation Adminis-
tration and US Census Bureau statistics. Published ATT inci-
dence estimates varied across patient risk factors and distance
ﬂown, ranging from zero to 455 events per 100,000 ﬂights.
Treatment efﬁcacy estimates for the relative risk reduction of
ATT during and immediately following air travel were obtained
from published literature. The model assumed prophylactic
therapy use prior to each ﬂight; for compression stockings, one
set was issued per patient for all ﬂights. Cost inputs included
medical charges for incident ATT treatment (extrapolated from
the literature) and prophylactic treatments (estimated from
wholesale acquisition costs). Five reiterations of the model were
performed to test all ATT incidence estimates. Incremental cost-
effectiveness ratios (ICERs) were calculated for prophylaxis
versus no treatment. RESULTS: In 4 of 5 risk scenarios, ICERs
for aspirin prophylaxis was dominant, with potential MCO cost
savings ranging from $436,700 to $1,251,500. For compression
stockings, ICERs were dominant for patients taking long-haul
ﬂights only (>5000 miles), with potential cost savings of
$957,700 to $1,141,600. LMWH prophylaxis did not result in
cost savings under any scenario. Reducing the treatment efﬁcacy
estimates by up to 20% did not alter these results. CONCLU-
SION: Payment for prophylactic aspirin therapy for ATT pre-
vention in air travelers resulted in cost savings for a MCO, as
did payment for compression stockings for use during long-haul
ﬂights. MCOs that develop programs to provide prophylactic
therapies to air travelers could realize signiﬁcant cost savings.
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OBJECTIVES: Pharmacoeconomic analysis of extended pre-
ventive injection of enoxaparin after hip joint replacement 
and costing of one prevented case of deep venous thrombosis
(DVT) in the enoxaparin group compared to placebo in Russia.
METHODS: The pharmacoeconomic analysis was based on the
results of prospective, randomized, double controlled study of
the use of enoxaparin as extended DVT prophylaxis conducted
in a clinical center in Sweden (Bergqvist D. et al., 1996). The efﬁ-
ciency of extended prophylaxis by enoxaparin versus placebo in
hospital environment was studied during the trial. All patients
(n = 262) received a daily hypodermic injection of 40 mg of
enoxaparin after preventative hip joint replacement, on average
during 9 days of their hospitalization (open study period). After
that the patients were randomized in groups. 131 patients in the
placebo group and 131 patients in the enoxaparin group received
the treatment. It was suggested that the patients of both groups
be injected with 40 mg of enoxaparin daily, on average during
18.6 days. In the clinical trial the number of detected DVT in
each group was assumed as the most adequate index of efﬁciency.
21 and 45 DVT cases were detected in the enoxaparin and the
placebo group respectively. RESULTS: In Russia total costs of
extended prophylaxis after hip joint replacement in comparison
groups amounted to $186,272 in the enoxaparin group and
$159,584 in the placebo group. Costs per patient amounted to
$1422 in the enoxaparin group and to $1218 in the placebo
group. With the help of efﬁciency increment analysis, the cost of
one DVT case prevented by way of extended prophylaxis by
enoxaparin versus placebo amounted to $1112. CONCLU-
SION: According to the results of the pharmacoeconomic analy-
sis based on the ﬁndings of the clinical trial, the cost of one DVT
case prevented with the help of extended prophylaxis by enoxa-
parin versus placebo is $1112.
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OBJECTIVES: Given the changing statin marketplace, this study
compares the cost-effectiveness among generic statins (lovas-
tatin, pravastatin, simvastatin) and more effective branded
monotherapy statins (atorvastatin, rosuvastatin) for ﬁrst and
second tier placement consideration, respectively, in routine clin-
ical practice. METHODS: Retrospective electronic medical
record database study was conducted of newly prescribed statin
therapy during August 2003–March 2005. Effectiveness of each
statin in reducing LDL-C and attaining National Cholesterol
Education Panel Adult Treatment Panel III LDL-C goal was eval-
uated using multivariate regressions after adjusting for baseline
LDL-C, demographics, comorbidities, and therapy duration.
Cost-effectiveness from a payer perspective was estimated for
rosuvastatin and atorvastatin (branded statins), and separately
for lovastatin, simvastatin and pravastatin (generic statins).
Annualized costs for statin (wholesale acquisition cost, WAC)
and titration were included. RESULTS: Of 10,421 eligible
patients, adjusted LDL-C reduction was signiﬁcantly greater (p
< 0.001) with rosuvastatin (−31.6%) than atorvastatin (−21.9%)
and other generic statins (−19.1% to −13.9%). Average dose of
rosuvastatin was 12 mg vs. 17–35 mg for other statins. Among
patients not at goal at baseline, the adjusted percentage of mod-
erate/high risk patients attaining LDL-C goal was higher (p <
0.001) for rosuvastatin (76.1%) versus atorvastatin (72.6%) and
other statins (57.6%–65%). Rosuvastatin was more effective
and less costly than atorvastatin in terms of cost per patient
reaching goal (in high and moderate risk patients) and in terms
of percent LDL-C lowering. Simvastatin and pravastatin
